FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?
This article was originally published in The Tan Sheet
Executive Summary
Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.
You may also be interested in...
Draft Guidance More Than Meets The Eye? Senators Seek Answers From FDA
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, putting companies in a difficult position.
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.
Lawsuit Seeking FDA Triclosan Action Stays Alive On Appeal
A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.